Sangamo Therapeutics, Inc. (LON:0R1D)

Market Cap	44.47M -56.6%
Revenue (ttm)	26.17M -45.8%
Net Income	-93.40M
EPS	-0.29
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	267,724
Open	0.1410
Previous Close	0.1360
Day's Range	0.1410 - 0.1699
52-Week Range	0.0300 - 0.7700
Beta	1.40
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Sangamo Therapeutics

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease; Phase 1/2 clinical trial to evaluate the safety and tolerability of the investigational ge...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1995
• Employees: 142
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0R1D

Financial Performance

In 2025, Sangamo Therapeutics's revenue was $39.55 million, a decrease of -31.57% compared to the previous year's $57.80 million. Losses were -$122.93 million, 25.5% more than in 2024.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 12, 2026

Data Sources Report a data error